Entities / Company
Arcturus Therapeutics.
biotech company
- Reports this week
- 0
- Active events
- 1
- Connections
- 37
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
One to three months ago
-
Arcturus Therapeutics and Thermo Fisher Scientific entered a collaboration for the development of ARCT-032, with Thermo Fisher providing manufacturing and services.Some support1 report1 development inside
-
Arcturus Therapeutics is conducting clinical trials in Turkey and Israel, with Thermo Fisher offering potential support if Phase III proceeds.Some support1 report
-
Zenas BioPharma and Arcturus Therapeutics are listed on Nasdaq, competing in the healthcare investment market.Some support2 reports
-
Analyst upgrades and price targets for Arcturus Therapeutics stock were reported on July 9, 2026, alongside stock price movement below its 50-day average.Some support2 reports
Gone quiet
No new reports in 90+ days-
Arcturus Therapeutics hosted Key Opinion Leader (KOL) presentations featuring Johannes Häberle and Marshall Summar on June 23, 2025.Speculative1 report
-
ARCT-810, an mRNA therapeutic candidate, is being developed by Arcturus Therapeutics, with Dr. Juergen Froehlich serving as Chief Medical Officer.Speculative1 report
-
Arcturus Therapeutics shares underperformed the S&P 500 this year, based on events of August 12, 2025.Some support1 report1 development inside
-
Arcturus Therapeutics announced its financial results from San Diego.Some support1 report
-
Arcturus Therapeutics, a company, is based in San Diego, California, and has a joint venture in Japan.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Around Arcturus Therapeutics this week
News at the entities that move Arcturus Therapeutics most-
Payne StructuralAn alumnus connected to Payne donated $50 million to the University of Missouri to establish a new energy innovation center.Moves Arcturus Therapeutics
-
Cohen StructuralTrump's administration deported citizens to El Salvador while Cohen and Green introduced articles of impeachment against Trump.Moves Arcturus Therapeutics
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Arcturus Therapeutics
-
Europe OperationalThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Arcturus Therapeutics
-
MarketBeat Mentioned togetherMarketBeat aggregates data on IDT Corporation stock performance.Moves Arcturus Therapeutics
-
Zenas OperationalZenvia Inc. utilized the LinkedIn platform for its social media presence.Moves Arcturus Therapeutics
Connections
The 9 strongest of 37, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Payne Structural
Payne serves as the President and CEO of Arcturus Therapeutics.
-
Cohen Structural
Cohen serves as the Chief Medical Officer of Arcturus Therapeutics.
-
Nasdaq Structural
Arcturus Therapeutics is listed on the Nasdaq exchange.
-
Turkey Shared context
Arcturus Therapeutics is conducting clinical trials within the borders of Turkey.
-
Europe Operational
Europe functions as a necessary patient market for Arcturus Therapeutics' OTC deficiency treatments.
-
Zenas Operational
Both entities are healthcare companies actively competing for investment opportunities.
-
MarketBeat Mentioned together
MarketBeat aggregates and summarizes current financial ratings and price targets for Arcturus Therapeutics.
-
San Diego Shared context
Arcturus Therapeutics is located and operates within the geographical context of San Diego.
Show all 9 connections
-
Biofrontera Mentioned together
The two companies are co-mentioned as part of the biotech sector experiencing rating changes.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
2 eventsJuly 2026
2 events- Arcturus Therapeutics and Thermo Fisher Scientific entered a collaboration for the development of ARCT-032, with Thermo Fisher providing manufacturing and services.
- Analyst upgrades and price targets for Arcturus Therapeutics stock were reported on July 9, 2026, alongside stock price movement below its 50-day average.
Show 1 earlier month
June 2026
5 events- Arcturus Therapeutics hosted Key Opinion Leader (KOL) presentations featuring Johannes Häberle and Marshall Summar on June 23, 2025.
- ARCT-810, an mRNA therapeutic candidate, is being developed by Arcturus Therapeutics, with Dr. Juergen Froehlich serving as Chief Medical Officer.
- Arcturus Therapeutics shares underperformed the S&P 500 this year, based on events of August 12, 2025.
- Arcturus Therapeutics announced its financial results from San Diego.
- Arcturus Therapeutics, a company, is based in San Diego, California, and has a joint venture in Japan.